A noninvasive sizing method to choose fi tted Amplatzer septal occluder by transthoracic echocardiography in patients with secundum atrial septal defects a safe and ideal method to measure interatrial defect and choose the occluding device, respectively. With our experience, the sizing based on TTE is generally easier than measurement from the balloon sizing.
Introduction
Percutaneous transcatheter closure of atrial septal defects (ASDs) has been established as a safe and effective treatment alternative to surgery. [1] [2] [3] [4] During the traditional procedure, fl uoroscopy with the waist of a compliant balloon is used to determine the appropriate size of the closure device and defect sizing. More recently, transesophageal echocardiography (TEE) 5, 6 and intracardiac echocardiography (ICE) [7] [8] [9] [10] [11] have been successfully used as guiding methods and defect sizing during these procedures. Owing to the length of the procedure, the use of TEE requires general anesthesia or deep sedation. Recently, live threedimensional transthoracic echocardiography (3D TTE) has offered en-face views of patent foramen ovale or ASD with precise defi nition of its shape, thus guiding the procedure of transcatheter closure without general anesthesia. Unfortunately, in some real-time three-dimensional echocardiography machines, the ASD dimensional reconstructions are available off-line only. The average acquisition time of a single dataset is approximately 2-3 min. The time required for the off-line processing of the ultrasound data may take up to 20 min. A noninvasive technique that would permit en-face imaging of the atrial septum and reduce the procedure time for ASD sizing and for closure assessment would be optimal. We would like to utilize live 3D TTE plus 2D TTE, a newer noninvasive technology that may provide comprehensive assessment of ASD diameter and guidance in transcatheter ASD closure later. However, the accuracy in defect sizing and adequate closure device using transthoracic echocardiography (TTE) has not been investigated.
Abstract
To simplify the conventional procedure, we developed a technique for transcatheter closure of atrial septal defects (ASDs) under transthoracic echocardiographic (TTE) sizing without balloon sizing. At present, device closure of interatrial communication has become a well-established technique to adequately treat severe leftto-right shunt associated with ASDs. During the traditional procedure, fl uoroscopy with the waist of a compliant balloon is used to determine the appropriate size of the closure device and defect sizing. Choice of adequate closure device using transthoracic echocardiography (TTE) has been hitherto unreported. Between December 2002 and August 2004, 40 patients (15 males, 25 females, mean age 11.7 ± 7.8 years) with secundum ASDs underwent transcatheter closure at our institution. In group 1, 30 patients had the procedure by balloon sizing and TTE sizing. In 10 patients (group 2), TTE sizing was used as the sole tool for selecting device size and the device size was chosen to be based on the Amplatzer septal occluder (ASO) size and TTE size ratio in group 1. The procedure was performed under continuous transesophageal echocardiographic monitoring with general anesthesia. A correlation was found between TTE and stretched balloon sizing diameter SBD (y = 1.2645x − 1.4465; R 2 = 0.9861), and between TTE size and ASO size (y = 1.3412x − 1.2864; R 2 = 0.9929) in group 1. In group 2, a statistical correlation between TTE and ASO (y = 1.3419x − 0.1172; R 2 = 0.9934) was also found. Good linear regression between TTE size and ASO chosen size was noted in group 1 and group 2 (R 2 = 0.99). In group 2, successful device implantation was accomplished in all patients whose device size was chosen to be based on the ASO and TTE ratio in group 1. Transthoracic echocardiographic sizing is Therefore, the purpose of our study was to evaluate TTE for sizing of ASDs.
Patients and methods

Study patients
From December 2002 to August 2004, 42 consecutive patients who underwent percutaneous interatrial septal defect closure were included in the study. Before the procedure, all patients had undergone a TTE examination to determine the number, position, and size of the defects. In group 1, with 30 patients, the stretched balloon sizing was used during the examination procedure of interatrial septal defects in addition to the TTE measurement. In group 2, we excluded from the study one patient with multiple ASDs and one patient in whom large ASD was revealed at TTE imaging. For the remaining 10 patients, the TTE measurement of interatrial septal defect was used alone. In total, 40 patients formed the study population. The mean age of the 40 patients (15 males, 25 females) was 11.7 ± 7.8 years (SD) (age range 4-40 years). All patients had a complete blood count, chemistries, renal function, and a hypercoagulability workup before closure. The procedure was performed under general anesthesia, with the TEE-guided ASD device closure. All the participants signed informed consent for the procedure.
Echocardiography
The echocardiograms and the echocardiographic measurements for the study were performed with an VingMed sound (GE) or ultrasound 7500 (HP) (2.5-8 MHz). An ultrasound 7500 (HP) or Vivid 7 sound (GE) multiplane probe was used for TEE through the catheterization process. The initial TTE showed the location of the ASD, its septal rim, and its diameter and also enabled us to measure the length of the interatrial septum in standard subcostal, apical, and parasternal views. The defect was measured in each of these views and a maximum defect diameter determined. These measurements were used to assess the feasibility of transcatheter closure with the Amplatzer septal occluder.
Atrial septal defect closure procedure, balloon sizing, and closure device Defects were closed percutaneously using an Amplatzer Septal Occluder (AGA Medical, Golden Valley, MN, USA), 12,13 using techniques previously described. 14, 15 In the catheterization, a biplane transoesophageal echocardiogram (TEE) was done under general anesthesia to evaluate the location of the defects and its margins. Vascular access was obtained from the femoral vein, and heparin (50-100 IU/kg) and antibiotics (cefazoline gentamicin) were given. After making a complete hemodynamic evaluation, an anomalous pulmonary vein connection was excluded by angiocardiography. In group 1 (n = 30), "stretched" diameter of the ASD was measured using an Amplatzer sizing balloon (AGA Medical). Under transesophageal echocardiographic and fl uoroscopic guidance the balloon was gradually infl ated with diluted contrast medium (1 : 4) until the shunting was not visible. The stretched balloon diameter (SBD) was defi ned as the smallest balloon size that completely occluded the ASD and was measured by TEE and fl uoroscopy. 16 After measuring the stretched balloon sizing diameter, the balloon was removed and reinfl ated with the same amount of contrast medium. It was passed through a sizing plate to recheck the stretched diameter of the defect. A device with a waist diameter similar to, or in large defects up to 2 mm bigger than, the stretched ASD diameter was chosen. In group 2 (n = 10), TTE diameter of the ASD was measured alone without balloon sizing. Selection of ASD occluder device was made based on the TTE using a regression equation in group 1.
After the initial assessment of ASD size, the long sheath over the exchange guide wire into the left upper pulmonary vein, the device was inserted and deployed under fl uoroscopic and TEE guidance, as described in various publications. A secure and stable position of the occluder within the defects was checked by a gentle pushing and pulling of the delivery cable. The device and adjacent structures were then examined by TEE to ensure that there was no encroachment of the device on the atrioventricular valves or the right pulmonary veins. After releasing the device from the cable by unscrewing it, a fi nal TEE examination was undertaken to demonstrate the position of the device and any residual shunting. After ASD closure the patients remained in the hospital for one night with ECG monitoring for 6-8 h. Before discharge an ECG and a TTE examination were performed.
Patients were discharged, and the taking of aspirin 2-3 mg/kg per day for 6 months was prescribed to protect against thrombosis formation on the device. Follow-up examinations including ECG and TTE were scheduled at 1, 3, 12, 24, and 36 months after the procedure.
Statistical analysis
Patient and ASD characteristics are evaluated as mean ± SD. Student's t-test was used to compare continuous variables. Statistical signifi cance was defi ned as P < 0.05. Linear regression analysis was used to compare TTE sizing diameter with stretched balloon size and Amplatzer septal occluder size.
Results
In group 1, 30 patients (12 males, 18 females; mean age 12.6 ± 8.6 years) underwent percutaneous interatrial septal defect closure by use of TTE sizing and stretched balloon sizing of interatrial septal defects. Individual patient demographics and characteristics of their ASD are given in Table 1 . The ASD diameter was different frequently under TTE and TEE sizing. The ratio of different diameter depending on the echo view with TTE and TEE was 90%. The statistical correlations between TTE size and stretched balloon size, TTE size, and Amplazter size are given in Figs. 1 and  3 . In group 1, the statistical correlations between TTE size and TEE size (y = 1.2658x − 1.9693; R 2 = 0.989) are given in Fig. 2 . The device delivery and implantation were successful without any complications in all but two patients. In these patients, the standard chosen device by stretched balloon sizing was deployed, but failed to anchor in the interatrial septum, and had to be successfully redeployed using a size 2 mm larger than standard Amplatzer. The TTE method exhibited excellent correlation (y = 1.3412x − 1.2864; R 2 = 0.9929) (Fig. 3) . In group 2, with 10 patients (3 males, 7 females; mean age 9.4 ± 3.6 years), TTE sizing was used as the sole imaging tool for guiding device selection. Base on the ASO and TTE ratio in group 1, we chose the Amplatzer to be 1.2 to 1.35 times the TTE diameter of the atrial septal defects. The larger the TTE sizing diameter of ASD, the larger the chosen ASO and TTE ratio. Individual patient demographics and characteristics of their ASD are given in Table 2 . The statistical correlations between TTE size and ASO (y = 1.3419x − 0.1172; R 2 = 0.9939) are given in Fig. 4 . Successful device implantation was accomplished in all 10 patients. The success rate in TTE sizing was the as same as that for sizing with stretched balloon. The TTE size 
Complications
No stenotic lesions on superior vena cava, atrioventricular valves, and coronary sinus due to the device implantation occurred during the procedure. Similarly, there were no air embolisms, device dislocations, or arrhythmias.
Follow-up
During the mean follow-up period of 22.4 ± 10.2 months, there were no incidences of shunt through effect for any of the edges of the device, and no major or minor vascular events.
Discussion
With the extensive use of echocardiography for patient selection and the development of new occluder systems, the transcatheter closure of ASDs has recently become an increasingly attractive alternative to surgical repair in many medical centers. The most important reason is that the Amplatzer septal occluder is self-expandable and the device's waist between the left and right retention discs is a polyester fabric stent, resulting in self-centering within the defect. Thus the Amplatzer occluder requires only a small rim around the defect for fi rm cross-clamping by the retention discs. 17 The morphologic characteristics of ASD including size measurement and spatial relationship between the ASD and neighboring structures are of paramount importance for the successful deployment of a transcatheter septal occluder. Pediatric interventional cardiologists need to know the exact size and morphology of ASD so that the therapeutic device can be safely deployed.
The most frequently used method for ASO device selection is the balloon-sizing method. However, this method has its disadvantages. Balloon sizing may be associated with two pitfalls. Firstly, balloon sizing can itself cause damage, enlarging the defect by tearing the fl ap valve of the septum primum. Secondly, it may cause arrhythmias or obstruction of venous return. Some investigators in the United States and Europe do not use sizing balloon and they simply add 3 mm to the ASD size measured by TEE (or TTE). In our study, several patients' Amplazter septal occluder size was bigger than 3 mm to compare with ASD size by TEE in group 1. Therefore, the simple method is not adequate.
Transthoracic echocardiography could produce novel views of secundum type ASDs and provide quantifi cation of the size of the defect. Transthoracic echocardiography offers additional special information in ASD without extending examining time, permits quantitative recording of septal defect, and enhances the understanding of complex cardiac anatomy and elucidation of the disease mechanism. It is a potentially valuable clinical tool for diagnosing and managing patients with congenital heart disease. With increasing echocardiographic operator experience and skill, noninvasively sizing ASDs to select the proper Amplatzer septal occluder for percutaneous closure of ASD is demanding. As it is diffi cult to examine defects in older patients using TTE accurately, we excluded many patients who were older than 40 years. However, to avoid completely the use of balloon sizing, we concur that there is a need for accurate transthoracic echocardiographic measurement before a transcatheter closure.
In the present study, echocardiography alone was provided to determine the defect diameter in 10 patients. The results demonstrate TTE sizing in transcatheter device closure to be as good as conventional balloon sizing. Further- more, there is good linear regressive correlation between TTE size and ASO size (R 2 = 0.99), and the success rate in TTE sizing was the same as that in sizing with a stretched balloon. The TTE sizing also reduces fl uoroscopy time and procedure times. Especially in young individuals, reduction of radiation exposure is of utmost importance, besides which the additive risk of arrhythmia during balloon sizing must also be considered an unresolved problem.
Transthoracic echocardiographic sizing for ASD occluder
The atrial septum should be visualized from multiple aspects in order to assess the size, shape, and location of the defect as well as its relationship to adjacent structures. Particular care should be taken to assess the relationship of the defect to the superior and inferior venae cavae, the pulmonary veins, and the coronary sinus. Additional views are used to detect any associated anomalous pulmonary venous return. In the subcostal four-chamber view, ostium secundum atrial septal defects can be visualized in the midportion of the atrial septum. These defects are bordered on all sides by septal tissue. In addition, this view permits us to distinguish superior vena caval defects, inferior vena caval defects, and coronary sinus defects from secundum defects. In the subcostal sagittal view, sweeping the transducer from right to left allows identifi cation of the largest dimension of the atrial septal defect. The combined use of these two subcostal views permits accurate measurement of atrial septal defect and evaluation of the amount of tissue rim surrounding the defect, which is important for the Amplatzer septal occluder. Because we wanted to size the atrial septal defects accurately, we planned an imaging plane including these two subcostal views with Doppler color fl ow. In patients in whom the subcostal views are diffi cult to obtain (e.g., in obese and older patients, or patients with subxyphoid chest tubes), the low parasternal four-chamber view provides an alternative method for imaging the atrial septum. When the echocardiographic low parasternal fourchamber view was used under special conditions, the diameter of the atrial septal defect was usually shorter than in the subcostal views. Therefore, the different ratio of ASO and TTE was induced. In this study, the ASO and TTE ratio ranged from 1.20 to 1.35 (mean = 1.33). In some patients, their ASDs may not be round and the diameter of ASD is different depending on the view, so views for imaging the atrial septal defect should be chosen to maximize echo refl ectivity from the thin atrial septum. The atrial septal defect should be visualized from multiple aspects in order to assess the size and shape. In addition to using twodimensional echocardiography, we also use color Doppler techniques to provide additional diagnostic information. Color Doppler echocardiography is particularly useful for confi rming the presence of an atrial septal defect in those patients in whom direct imaging of the atrial septum is technically inadequate and for sizing the atrial septal defect. Moreover, this technique is useful for distinguishing a true atrial septal defect from artifactual echocardiographic dropout in the thin region of the fossa ovalis. The basic question as to whether the procedure with TTE sizing should be further refi ned by more widespread use in other experienced centers has to be discussed. We are convinced, however, that accurate TTE measurement justifi es the transcatheter closure of ASDs without the routine use of balloon sizing.
Study limitations
Some limitations inherent to this technique must be taken into account. Firstly, our study was limited to some extent because we have only 40 patients. Secondly, the multiple ASDs, large ASD (TTE diameter ≥30 mm), and ASD with anomalous pulmonary venous connection (APVC) were generally excluded when selecting for TTE sizing to choose the Amplatzer device. Whether the procedure is suitable for larger defects and multiple defects remains to be determined. Thirdly, a signifi cant number of secundum atrial septal defects appear to be unsuitable candidates for device closure because of unfavorable morphology. 18 The procedure, however, was undertaken by a single operator thus minimizing potential differences in the level of experience. Fourthly, the follow-up period was relatively short and this limited our ability to detect potential differences in the clinical outcome.
In conclusion, TTE sizing can be considered a safe tool for sizing device closure of ASDs. Our experience shows that for the selection of the appropriate size of the ASD occluding device, the balloon-sizing procedure may be skipped with precordial transthoracic echocardiography.
